Skip to content

The clinical application value of the prediction of cervical lesions by HPV cervical cell gene integration test

Comparison of the results of a new HPV cervical cell gene integration test system with the commercial HPV test system and its clinical application

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000028798
Enrollment
Unknown
Registered
2020-01-04
Start date
2020-03-01
Completion date
Unknown
Last updated
2020-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer

Interventions

integration,&#32
the&#32
gene&#32
Gold Standard:Pathology
Index test:The&#32
of&#32

Sponsors

The Affliated Cancer Hospital of Xinjiang Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: The first visit to the gynecological clinic, and the total amount of residual DNA extract after HPV examination in the laboratory department can meet the requirements of HPV typing test by Zhongshan Da'an kit (pcr-reverse point hybridization method) and HPV host cell genome integration test.

Exclusion criteria

Exclusion criteria: The remaining DNA extract is insufficient for further testing.

Design outcomes

Primary

MeasureTime frame
the number of HPV gene integration;The length of HPV gene integration;

Countries

China

Contacts

Public ContactFeng Yangchun

The Affliated Cancer Hospital of Xinjiang Medical University

paopao1987123@163.com+86 15214804951

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026